FDA Panel Approves Novo Nordisk Diabetes Drug

Oct 18, 2017

Reuters

The conclusion of an advisory panel to the U.S. FDA concluded was that Novo Nordisk A/S’s new diabetes drug semaglutide was effective, reasonably safe and should be approved, according to a Reuters article.

The panel reportedly voted 16-0 with one abstention recommending the drug's approval. The drug falls in a class of glucagon-like peptide-1 (GLP-1) analogs, which imitate an intestinal hormone that stimulates the production of insulin.

Read the full story